Literature DB >> 7680142

Prolongation of survival for carcinoma at the hepatic duct confluence.

S Tashiro1, T Tsuji, K Kanemitsu, Y Kamimoto, T Hiraoka, Y Miyauchi.   

Abstract

BACKGROUND: Because of poor long-term results in resection for carcinoma at the hepatic duct confluence, we have adopted a more aggressive approach.
METHODS: The records of 46 patients with carcinoma of the hepatic duct confluence were reviewed. Twenty-four patients underwent hepatic resection and 10 underwent local resection. The remaining 12 patients had unresectable lesions and received palliative treatment. Out of 24 patients who underwent hepatic resection, 17 underwent combined resection of the caudate lobe. Five patients who underwent hepatic resection and three patients who underwent local resection received intraoperative radiotherapy in a dose of 30 Gy of electron beam. Postoperative radiotherapy with a total dose of 50 Gy of external electron beam was performed for five patients who underwent nonradical hepatic resection and one patient who underwent nonradical local resection.
RESULTS: None of the 10 patients who underwent local resection and only 1 (4.2%) of 24 patients who underwent hepatic resection died in the hospital. Among patients who underwent hepatic resection, the 1-, 3-, and 5-year survival rates were 62%, 37%, and 25%, respectively, whereas the respective survival rates in the group that underwent local resection were 50%, 20%, and 20%. The 1-, 3-, and 5-year survival rates for patients who underwent combined caudate lobectomy were 69.7%, 53.4%, and 23%, respectively, compared with 57.1%, 26%, and 14.3% for those who did not. The median survival time for patients who received radiotherapy after nonradical resection was 17 months, compared with 5 months for those who did not.
CONCLUSIONS: These results suggest that major hepatic resection combined with caudate lobectomy should be performed for carcinoma of the heptic duct confluence. Postoperative radiotherapy after nonradical resection may be effective in prolonging survival.

Entities:  

Mesh:

Year:  1993        PMID: 7680142

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  12 in total

1.  Surgical management of hilar cholangiocarcinoma: the Nagoya experience.

Authors:  Hideki Nishio; Masato Nagino; Yuji Nimura
Journal:  HPB (Oxford)       Date:  2005       Impact factor: 3.647

2.  Lymph node metastasis from hilar cholangiocarcinoma: audit of 110 patients who underwent regional and paraaortic node dissection.

Authors:  Y Kitagawa; M Nagino; J Kamiya; K Uesaka; T Sano; H Yamamoto; N Hayakawa; Y Nimura
Journal:  Ann Surg       Date:  2001-03       Impact factor: 12.969

Review 3.  Improved surgical results for hilar cholangiocarcinoma with procedures including major hepatic resection.

Authors:  T Kosuge; J Yamamoto; K Shimada; S Yamasaki; M Makuuchi
Journal:  Ann Surg       Date:  1999-11       Impact factor: 12.969

Review 4.  Surgical treatment in proximal bile duct cancer. A single-center experience.

Authors:  R Pichlmayr; A Weimann; J Klempnauer; K J Oldhafer; H Maschek; G Tusch; B Ringe
Journal:  Ann Surg       Date:  1996-11       Impact factor: 12.969

5.  Results of surgical resection for patients with hilar bile duct cancer: application of extended hepatectomy after biliary drainage and hemihepatic portal vein embolization.

Authors:  Seiji Kawasaki; Hiroshi Imamura; Akira Kobayashi; Terumasa Noike; Shiro Miwa; Shin-ichi Miyagawa
Journal:  Ann Surg       Date:  2003-07       Impact factor: 12.969

6.  Initial presentation and management of hilar and peripheral cholangiocarcinoma: is a node-positive status or potential margin-positive result a contraindication to resection?

Authors:  Kevin Tri Nguyen; Jennifer Steel; Tsafrir Vanounou; Allan Tsung; J Wallis Marsh; David A Geller; T Clark Gamblin
Journal:  Ann Surg Oncol       Date:  2009-09-23       Impact factor: 5.344

7.  Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors.

Authors:  A Nakeeb; H A Pitt; T A Sohn; J Coleman; R A Abrams; S Piantadosi; R H Hruban; K D Lillemoe; C J Yeo; J L Cameron
Journal:  Ann Surg       Date:  1996-10       Impact factor: 12.969

8.  Intraportal endovascular ultrasonography in the diagnosis of portal vein invasion by pancreatobiliary carcinoma.

Authors:  T Kaneko; A Nakao; S Inoue; A Harada; T Nonami; S Itoh; T Endo; H Takagi
Journal:  Ann Surg       Date:  1995-12       Impact factor: 12.969

9.  Is parenchyma-preserving hepatectomy a noble option in the surgical treatment for high-risk patients with hilar bile duct cancer?

Authors:  Hiroshi Shimada; Itaru Endo; Mitsutaka Sugita; Hideki Masunari; Yoshiro Fujii; Kuniya Tanaka; Hitoshi Sekido; Shinji Togo
Journal:  Langenbecks Arch Surg       Date:  2003-02-28       Impact factor: 3.445

10.  Hepatic resection combined with portal vein or hepatic artery reconstruction for advanced carcinoma of the hilar bile duct and gallbladder.

Authors:  Hiroshi Shimada; Itaru Endo; Mitsutaka Sugita; Hideki Masunari; Yoshiro Fujii; Kuniya Tanaka; Koichi Misuta; Hitoshi Sekido; Shinji Togo
Journal:  World J Surg       Date:  2003-08-21       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.